-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2025-04-08
ARGX:NSD- (USD)
COMMON STOCK | Biotechnology |
Last Closing
USD 548.93Change
-1.07 (-0.19)%Market Cap
USD 37.97BVolume
0.53MVerdict
Verdict
Values as of: 2025-04-08
COMMON STOCK | Biotechnology |
Last Closing
USD 548.93Change
-1.07 (-0.19)%Market Cap
USD 37.97BVolume
0.53MVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
VRTX | Vertex Pharmaceuticals Inc |
-14.60 (-2.92%) |
USD 126.52B |
REGN | Regeneron Pharmaceuticals Inc |
-8.63 (-1.55%) |
USD 69.68B |
ALNY | Alnylam Pharmaceuticals Inc |
-0.43 (-0.19%) |
USD 30.51B |
ONC | BeiGene, Ltd. |
-10.70 (-4.48%) |
USD 26.35B |
RPRX | Royalty Pharma Plc |
-0.26 (-0.80%) |
USD 19.31B |
SMMT | Summit Therapeutics PLC |
-1.57 (-6.38%) |
USD 14.57B |
INSM | Insmed Inc |
-0.87 (-1.22%) |
USD 12.52B |
INCY | Incyte Corporation |
-0.73 (-1.25%) |
USD 11.72B |
BMRN | Biomarin Pharmaceutical Inc |
-1.20 (-2.00%) |
USD 11.50B |
MRNA | Moderna Inc |
-1.05 (-4.00%) |
USD 9.91B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
DXID:CA | Dynamic Active Innovation.. | 4.55 % | 0.00 % |
-0.66 (-4.27%) |
CAD 0.03B |
BMED | BlackRock Future Health E.. | 3.48 % | 0.00 % |
-0.15 (-4.27%) |
USD 2.67M |
SRHE:LSE | Amundi Index Solutions - .. | 2.98 % | 0.00 % |
+31.50 (+-4.27%) |
USD 0.23B |
HEAL:SW | iShares Healthcare Innova.. | 2.50 % | 0.00 % |
-0.03 (-4.27%) |
USD 1.05B |
XSDR:LSE | Xtrackers MSCI Europe Hea.. | 2.43 % | 0.00 % |
-28.00 (-4.27%) |
USD 0.21B |
2B70:F | iShares NASDAQ US Biotech.. | 2.12 % | 0.00 % |
-0.16 (-4.27%) |
USD 0.52B |
TEET:LSE | VanEck Sustainable Europe.. | 1.47 % | 0.00 % |
+0.12 (+-4.27%) |
USD 0.06B |
TEET:SW | 1.36 % | 0.00 % |
N/A |
N/A | |
TEGB:LSE | VanEck Sustainable Europe.. | 1.25 % | 0.00 % |
+9.50 (+-4.27%) |
N/A |
TSWE:SW | VanEck Sustainable World .. | 0.62 % | 0.00 % |
+1.45 (+-4.27%) |
USD 0.93B |
AGED:SW | iShares Ageing Population.. | 0.61 % | 0.00 % |
+0.03 (+-4.27%) |
N/A |
TSGB:LSE | VanEck Sustainable World .. | 0.61 % | 0.00 % |
-0.06 (-4.27%) |
USD 0.91B |
TSWE:LSE | VanEck Sustainable World .. | 0.49 % | 0.00 % |
-0.25 (-4.27%) |
N/A |
BBH | VanEck Biotech ETF | 0.00 % | 0.35 % |
-2.77 (-4.27%) |
USD 0.40B |
BIB | ProShares Ultra Nasdaq Bi.. | 0.00 % | 0.95 % |
-1.49 (-4.27%) |
USD 0.06B |
FBT | First Trust NYSE Arca Bio.. | 0.00 % | 0.57 % |
-2.85 (-4.27%) |
N/A |
AGED:LSE | iShares Ageing Population.. | 0.00 % | 0.00 % |
-0.03 (-4.27%) |
N/A |
AGES:LSE | iShares IV Public Limited.. | 0.00 % | 0.00 % |
-0.38 (-4.27%) |
N/A |
DRDR:LSE | iShares Healthcare Innova.. | 0.00 % | 0.00 % |
N/A |
N/A |
HEAL:LSE | iShares Healthcare Innova.. | 0.00 % | 0.00 % |
-0.01 (-4.27%) |
N/A |
HLTH:LSE | SPDR® MSCI Europe Health.. | 0.00 % | 0.00 % |
-1.03 (-4.27%) |
N/A |
STW:PA | SPDR® MSCI Europe Health.. | 0.00 % | 0.00 % |
-1.02 (-4.27%) |
USD 0.72B |
DXSE:F | Xtrackers Stoxx Europe 60.. | 0.00 % | 0.00 % |
N/A |
N/A |
EXV4:F | 0.00 % | 0.00 % |
N/A |
N/A | |
SPYH:F | SSgA SPDR ETFs Europe II .. | 0.00 % | 0.00 % |
-1.00 (-4.27%) |
N/A |
2B70:XETRA | iShares Nasdaq US Biotech.. | 0.00 % | 0.00 % |
-0.06 (-4.27%) |
USD 0.52B |
2B77:XETRA | iShares Ageing Population.. | 0.00 % | 0.00 % |
-0.11 (-4.27%) |
USD 0.50B |
2B78:XETRA | iShares Healthcare Innova.. | 0.00 % | 0.00 % |
-0.05 (-4.27%) |
USD 1.05B |
DXSE:XETRA | Xtrackers - Stoxx Europe .. | 0.00 % | 0.00 % |
-1.57 (-4.27%) |
USD 0.14B |
ETLI:XETRA | L&G Pharma Breakthrough U.. | 0.00 % | 0.00 % |
-0.08 (-4.27%) |
USD 0.02B |
EXV4:XETRA | iShares STOXX Europe 600 .. | 0.00 % | 0.00 % |
-0.64 (-4.27%) |
USD 0.70B |
SPYH:XETRA | SPDR® MSCI Europe Health.. | 0.00 % | 0.00 % |
-1.58 (-4.27%) |
N/A |
TSWE:XETRA | VanEck Sustainable World .. | 0.00 % | 0.00 % |
-0.26 (-4.27%) |
N/A |
V3ET:XETRA | VanEck Sustainable Europe.. | 0.00 % | 0.00 % |
-0.16 (-4.27%) |
N/A |
IBBQ | Invesco Nasdaq Biotechnol.. | 0.00 % | 0.00 % |
-0.39 (-4.27%) |
USD 0.04B |
2B77:F | iShares Ageing Population.. | 0.00 % | 0.00 % |
-0.06 (-4.27%) |
N/A |
2B78:F | iShares Healthcare Innova.. | 0.00 % | 0.00 % |
-0.05 (-4.27%) |
N/A |
ESIH:F | Ishares VI PLC - Ishares .. | 0.00 % | 0.00 % |
+0.34 (+-4.27%) |
N/A |
ESIH:XETRA | iShares MSCI Europe Healt.. | 0.00 % | 0.00 % |
-0.04 (-4.27%) |
N/A |
HEAE:LSE | SPDR® MSCI Europe Health.. | 0.00 % | 0.00 % |
-0.22 (-4.27%) |
N/A |
STWX:SW | SPDR® MSCI Europe Health.. | 0.00 % | 0.00 % |
-2.02 (-4.27%) |
USD 0.66B |
SXDPEX:SW | iShares STOXX Europe 600 .. | 0.00 % | 0.00 % |
N/A |
USD 0.44B |
Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | -10.74% | 79% | B- | 62% | D | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | -10.74% | 79% | B- | 62% | D | ||
Trailing 12 Months | |||||||
Capital Gain | 42.90% | 92% | A | 92% | A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 42.90% | 92% | A | 92% | A | ||
Trailing 5 Years | |||||||
Capital Gain | 282.32% | 95% | A | 94% | A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 282.32% | 95% | A | 93% | A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 22.24% | 69% | C- | 78% | C+ | ||
Dividend Return | 22.24% | 69% | C- | 77% | C+ | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 22.81% | 94% | A | 71% | C- | ||
Risk Adjusted Return | 97.50% | 100% | F | 96% | N/A | ||
Market Capitalization | 37.97B | 100% | F | 98% | N/A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company had negative total cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector